(NASDAQ: ALXO) Alx Oncology Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.94%.
Alx Oncology Holdings's earnings in 2026 is -$101,695,000.On average, 6 Wall Street analysts forecast ALXO's earnings for 2026 to be -$122,158,804, with the lowest ALXO earnings forecast at -$147,032,768, and the highest ALXO earnings forecast at -$91,204,537. On average, 6 Wall Street analysts forecast ALXO's earnings for 2027 to be -$96,995,301, with the lowest ALXO earnings forecast at -$112,209,218, and the highest ALXO earnings forecast at -$66,330,572.
In 2028, ALXO is forecast to generate -$86,927,268 in earnings, with the lowest earnings forecast at -$108,339,934 and the highest earnings forecast at -$64,948,685.